FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.

November 21, 2025

Vol.51 No.43

By Mikkael A. Sekeres

Cancer Policy

Makary, Prasad describe FDA’s new “plausible mechanism pathway” to get bespoke therapies to market sans RCT

FDA Commissioner Marty Makary and Vinay Prasad, FDA’s chief medical and scientific officer and director of the agency’s Center for Biologics Evaluation and Research, jointly published a letter in The New England Journal of Medicine spelling out the rationale for FDA’s new “plausible mechanism pathway,” aimed at getting bespoke therapies to market without the need for a randomized controlled trial.

FDA grants full approval of Imdelltra in ES-SCLC

FDA granted full approval to Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. The decision to convert Imdelltra’s prior accelerated approval to a full approval is based on data from the global phase III DeLLphi-304 study.

November 21, 2025

Vol.51 No.43

Drugs & Targets

FDA approves Poherdy, first biosimilar to Perjeta, for breast cancer indication

FDA approved Poherdy (pertuzumab-dpzb) as an interchangeable biosimilar to Perjeta (pertuzumab). This is the first approval of a biosimilar for Perjeta.

November 21, 2025

Vol.51 No.43

Drugs & Targets

FDA approves epcoritamab-bysp for follicular lymphoma indications

FDA approved epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

November 21, 2025

Vol.51 No.43

Drugs & Targets

FDA approves Hyrnuo for HER2-mutated NSCLC

FDA has approved Hyrnuo (sevabertinib), an oral, reversible, tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.

November 21, 2025

Vol.51 No.43

FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma

YOU MAY BE INTERESTED IN

My introduction to, and lessons learned from, Rick Pazdur

Makary, Prasad describe FDA’s new “plausible mechanism pathway” to get bespoke therapies to market sans RCT

FDA grants full approval of Imdelltra in ES-SCLC

FDA approves Poherdy, first biosimilar to Perjeta, for breast cancer indication

FDA approves epcoritamab-bysp for follicular lymphoma indications

FDA approves Hyrnuo for HER2-mutated NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login